Loading
A phase 1/2 trial of BCG (50mg/instillation) + N-803 (400 μg/instillation) in bladder & urothelial cancer, run by ImmunityBio, Inc., active and no longer recruiting.
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer is a phase 1/2 interventional study registered as NCT02138734 by ImmunityBio, Inc., with 369 participants enrolled, started 2014-07-21 and due to reach its primary completion in 2026-09-30. Interventions recorded: BCG (50mg/instillation) + N-803 (400 μg/instillation) and BCG (50mg/instillation).
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares ImmunityBio, Nogapendekin alfa inbakicept and the tag pipeline.